Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports

@inproceedings{Jefferson2014RiskOB,
  title={Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports},
  author={Tom Jefferson and Mark Andrew Jones and Peter Doshi and Chris Del Mar and Rokuro Hama and Matthew J. Thompson and Igho J Onakpoya and Carl J Heneghan},
  booktitle={BMJ open},
  year={2014}
}
BACKGROUND The Cochrane risk of bias tool is a prominent instrument used to evaluate potential biases in clinical trials. In three updates of our Cochrane review on neuraminidase inhibitors, we assessed risk of bias on the same trials using different levels of detail: the trials in journal publications, in core reports, and in full clinical study reports. Here we analyse whether progressively greater amounts of information and detail in full clinical study reports (including trial protocols… CONTINUE READING
96
Twitter Mentions

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES